PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals
PAREXEL International Corporation, an innovator of global biopharmaceutical services, introduced a new, dedicated division to help emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively. PAREXEL utilizes different strategies and services such as consulting, patient recruitment, trial execution, and Real World Evidence programs in order to help companies reach their objectives.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025